Previous 10 | Next 10 |
Jefferies analyst David Windley downgraded Syneos Health (SYNH -8.0%) to Hold from Buy with a price target of $75, down from $101, making the stock fall 8%. The analyst sees few issues affecting 2022 as, weak 4Q core bookings challenge 2022 Clinical revenue growth with slowing CMD b...
MORRISVILLE, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the promotions of two senior internal leaders – Baba Shetty to President, Technology and Data Solutions, a...
CFRA has downgraded contract research organization Syneos Health (NASDAQ:SYNH) to hold on a potential risk to margins caused by share-based compensation and restructuring costs. The firm also cut its target price to $78 from $88 (~4% downside based on Tuesday's close). Analyst Stewart Glickma...
MORRISVILLE, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, will release its first quarter 2022 financial results on Friday, April 29th, 2022, p...
Medpace Holdings is a healthy business trading at a discount to its intrinsic value. Price target $193-200. The company has zero debt vs peer group average of $5.6B debt. Lower risk of permanent loss of capital vs peers. Medpace top-line in the past four years grew at 17.5% CAGR v...
Syneos Health was formed in 2017 via a merger between 2 Contract Research Organizations, INC Research and inVentiv Health. From a share price perspective progress was slow initially, before the stock price gained 98% between late 2020 - late 2021. CROs operate in an attractive mar...
The following slide deck was published by Syneos Health, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Syneos Health, Inc. 2021 Q4 - Results - Earnings Call Presentation
Syneos Health Inc. (SYNH) Q4 2021 Results Conference Call February 17, 2022 08:00 AM ET Company Participants Ronnie Speight - SVP, Investor Relations Alistair Macdonald - Chief Executive Officer Jason Meggs - Chief Financial Officer Michael Brooks - Chief Development Officer & Global Head...
Syneos Health press release (NASDAQ:SYNH): Q4 Non-GAAP EPS of $1.48 beats by $0.05. Revenue of $1.37B (+20.2% Y/Y) misses by $30M. For FY2022, the company expects revenue of $5.6B to $5.75B vs. consensus of $5.70B; Adjusted Diluted EPS of $4.98 to $5.24 vs. consensus of $5.19. For further d...
Highlights Fourth quarter revenue of $1,373.4 million increased 20.5% year-over-year. Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $357.1 million for the fourth quarter, a year-over-year decline of 72.9%...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...